article · Baylor University Medical Center Proceedings
Fezolinetant effectively reduces VMS in postmenopausal women at both 4 and 12 weeks, aligning with previous research. It also improves quality of life, with a promising safety profile. Given fezolinetant's potential for liver enzyme elevations, it is essential to monitor liver function at baseline and regularly thereafter (monthly for the first 3 months and at 6 and 9 months) to ensure patient safety. Further studies with larger sample sizes are needed to confirm these findings.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/08998280.2025.2491894
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
